Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors

MT Newswires Live02-24 22:39

Erasca (ERAS) said Tuesday that the US Patent and Trademark Office has issued a patent covering the composition of matter for Erasca's investigational drug ERAS-4001 to treat patients with KRAS-mutant solid tumors.

The patent, which is effective until June 2043, is titled "Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof," and also includes related compositions.

"With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending," Erasca quoted its chief executive officer, Jonathan Lim, as saying in a statement. "We look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613710104?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613710104","market":"sg","top_or_hot":-1,"title":"Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors","media":"MT Newswires Live","content":"<html><body><p> Erasca (ERAS) said Tuesday that the US Patent and Trademark Office has issued a patent covering the composition of matter for Erasca's investigational drug ERAS-4001 to treat patients with KRAS-mutant solid tumors.</p><p>The patent, which is effective until June 2043, is titled \"Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,\" and also includes related compositions.</p><p>\"With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending,\" Erasca quoted its chief executive officer, Jonathan Lim, as saying in a statement. \"We look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year.\"</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-24 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Erasca (ERAS) said Tuesday that the US Patent and Trademark Office has issued a patent covering the composition of matter for Erasca's investigational drug ERAS-4001 to treat patients with KRAS-mutant solid tumors.</p><p>The patent, which is effective until June 2043, is titled \"Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,\" and also includes related compositions.</p><p>\"With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending,\" Erasca quoted its chief executive officer, Jonathan Lim, as saying in a statement. \"We look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year.\"</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2613710104","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613710104","pubTimestamp":1771943957,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Erasca  said Tuesday that the US Patent and Trademark Office has issued a patent covering the composition of matter for Erasca's investigational drug ERAS-4001 to treat patients with KRAS-mutant solid tumors.The patent, which is effective until June 2043, is titled \"Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,\" and also includes related compositions.\"With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending,\" Erasca quoted its chief executive officer, Jonathan Lim, as saying in a statement. \"We look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Erasca授予治疗实体瘤的研究药物ERAS-4001美国专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1.5},"content_text":"Erasca (ERAS) said Tuesday that the US Patent and Trademark Office has issued a patent covering the composition of matter for Erasca's investigational drug ERAS-4001 to treat patients with KRAS-mutant solid tumors.The patent, which is effective until June 2043, is titled \"Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof,\" and also includes related compositions.\"With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending,\" Erasca quoted its chief executive officer, Jonathan Lim, as saying in a statement. \"We look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613710104","isCrawlerRequest":true}